🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

You can also find MND Australia Research on BlueSky now @mndaus-research.bsky.social

🔊 Calling all scientists and science communicators 🔊 Pint of Science AU are calling for expressions of interest to speak at their 2025 festival. This is a great opportunity to share your work with the community and refine your public speaking skills #pintAU

Good to see this Australian-led study ready for the next phase; Open-label phase 2a study to assess the safety and tolerability of trimetazidine in patients with ALS academic.oup.com/braincomms/art… Shyuan Ngo 🧠🔬🧫👩🏻‍🍳😻 Derik Steyn Ammar Al-Chalabi

Makes sense - researchers need to work with funders/community to make sure the knowledge produced is useful and what the community needs " futurecampus.com.au/2025/02/07/my-…

Our study on the safety and tolerability of Trimetazidine in #ALS @BrainComms Trimetazidine reduced oxidative stress markers and energy expenditure, warranting a follow up study. Ruben van Eijk Derik Steyn Ammar Al-Chalabi academic.oup.com/braincomms/adv…

Finding the right balance between compliance and patient recruitment is tough—but it matters. It's key to: ✔️ Spot potential challenges early ✔️ Listen to patient feedback & adapt ✔️ Keep transparency and trust at the center Find out more👇 eu1.hubs.ly/H0gLP190 #Genetics

Since 2009, the Sydney Brain Bank at NeuRA has collected, characterised, stored, and distributed human brain and spinal cord tissue for research into disorders of the #brain and #mind. The specialised laboratories are equipped for handling, dissecting, and staining human tissue

CNM-Au8 in ALS - HEALEY Platform Trial outcomes No significant positive effects. EAP underway. Previous trials showed efficacy in longer-term follow-up - Healey only 6-months Larger Phase 3 trial under consideration and Clene in discussions with FDA jamanetwork.com/journals/jama/…

Pridopidine in ALS - HEALEY Platform Trial Outcome "In this 24-week study, pridopidine did not impact the progression of ALS" Is 6-months enough to see change? Healey now moving to 9-month trials - hopefully that will produce more definitive outcomes jamanetwork.com/journals/jama/…

Stand with Australians affected by neurological conditions🤝 Neurological conditions are the leading cause of disability worldwide, yet in Australia, they haven’t received the support they deserve. #CountUsInNeuro is calling for change. Take action 👉 bit.ly/3CGZ5Rj

Some challenging ideas - a very well thought out hypothesis; Amyotrophic lateral sclerosis represents corticomotoneuronal system failure - Eisen - Muscle & Nerve - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/mu…

Genetic testing for #ALS #MND should go beyond identifying a single mutation. Even if a known genetic cause is found. A comprehensive analysis provides a clearer understanding of the condition and can help guide care &research efforts. Happy to help in this fantastic project.

Not specifically MND but the concussion/brain injury association with neurodegeneration is still not finalised Sports-related concussion not associated with long-term cognitive or behavioural deficits: the PROTECT-TBI study jnnp.bmj.com/content/early/…

Neurological Alliance Australia (NAA) (MND Australia area member) are advocating for the creation of a Taskforce for Neurological Conditions to urgently address six critical areas of need. It takes just a few minutes to send an email to your local MP countusin.good.do/naa/count-us-i…

A lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection Better alternative to intrathecal (spinal) injections Potential for MND gene therapies? Only tested in mice so far... nature.com/articles/s4156… news-medical.net/news/20250217/…

ALS is missing from the headlines today about roberta flack. she lived with the disease for the past two/three years, and it cruelly stole her voice first. rip, queen.

Rethinking phase 2 trials in amyotrophic lateral sclerosis academic.oup.com/brain/article/… Well-thought out discussion - basically if you want to run 6-month Phase 2 trials - use biomarkers for your go/no-go decision. If you want to use ALSFRS-R - you need a longer trial

pTDP-43 levels correlate with cell type–specific molecular alterations in the prefrontal cortex of C9orf72 ALS/FTD patients | PNAS pnas.org/doi/10.1073/pn… Interesting to see microglia changes are seen first then followed by oligodendrocytes and astrocytes - suggests cascade